Aflibercept 8 mg in Neovascular AMD-A Fast-Drying Anti-VEGF Drug: A Prospective Morpho-Functional Pilot Study.

Ophthalmol Ther · 2026 · PMC12901755 · PMID 41388185

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Four months after the loading phase, patients in the 8 mg group had better BCVA and lower CMT compared to the 2-mg group, suggesting that better early results with 8 mg are maintained in the follow-up; however, these differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.